-
The AHEAD Study - with participants in the Orlando region - examines whether the newly approved drug lecanemab can prevent or at least delay the appearance of Alzheimer's symptoms.
-
Scientists are digging into why a few people escape the rarest form of Alzheimer's, which is inherited and strikes young.
-
Facilitator Pamela Levin of the Alzheimer's Association said Art Connects ALZ is a relaxing program using watercolors . It's therapeutic but not art therapy or art instruction.
-
The FDA approved the use of Leqembi in January for patients with mild or early cases of dementia tied to Alzheimer’s. A year’s treatment runs about $26,500, and there are few options outside of self-pay.
-
The woman was unresponsive, and nurses were unable to detect her breathing. A state agency report found the facility "failed to ensure residents received dignified treatment and care at end of life."
-
The FDA overruled its own scientific advisers in approving Aduhelm, despite lack of proof that it met its promise of slowing patients' decline.
-
Sarasota's Roskamp Institute was the first to discover a protein that tends to form clumps in the brains of people with Alzheimer's. A new drug has been shown to reduce it.
-
The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.
-
Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.
-
For husbands and wives across Florida, Alzheimer's disease tests their vows. Can they do the hard things?